Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Lenalidomide for del(5q) and Non-del(5q) Myelodysplastic Syndromes

    ... independence is 2 years, mainly at the expense of neutropenia and thrombocytopenia in the first courses of therapy. ... of duration of response, and 50% incidence of grade 3 and 4 neutropenia and thrombocytopenia compared to del(5q) patients. Recent data ...

    Research Article last updated 11/05/2012 - 9:37am.

  2. Infections in myelodysplastic syndromes: a review

    ... are associated with a risk of severe infections. While neutropenia is likely the main predisposing factor, several other immune ... in myelodysplastic syndromes but can transiently worsen neutropenia, may increase the risk of infection and their severity in this ...

    Research Article last updated 07/31/2012 - 1:39pm.

  3. Infections in patients with aplastic anemia.

    ... difference in the infections that they incur. Prolonged neutropenia is one of the largest risk factors for the development of ... with the invasive mycoses and bacteria. Recovery from neutropenia is directly related to survival, and supportive care plays ...

    Research Article last updated 10/11/2011 - 5:58pm.

  4. Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations.

    ... with lower-risk MDS who have thrombocytopenia or neutropenia or have anemia that is unresponsive to other therapies. ...

    Research Article last updated 07/09/2013 - 3:03pm.

  5. Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol

    ... hematologic- thrombocytopenia (20 patients) and neutropenia (13 patients). The common non-hematologic AEs were infections ...

    Research Article last updated 09/13/2016 - 2:47pm.

  6. GATA2 deficiency-associated bone marrow disorder differs from idiopathic aplastic anemia

    ... been reported in a minority of patients with congenital neutropenia and aplastic anemia (AA). The bone marrow (BM) ...

    Research Article last updated 11/25/2014 - 9:57am.

  7. "Moderate" dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution.

    ... was considerable, mainly due to prolonged absolute neutropenia , which occurred regardless of pre-therapy blood counts and ...

    Research Article last updated 10/07/2014 - 8:33am.

  8. "Moderate" dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution

    ... was considerable, mainly due to prolonged absolute neutropenia , which occurred regardless of pre-therapy blood counts and ...

    Research Article last updated 09/24/2014 - 10:17am.

  9. An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes

    ... events >30% included diarrhea, fatigue, nausea, febrile neutropenia , and stomatitis. Results suggest modest activity in AML, ...

    Research Article last updated 08/04/2014 - 8:28am.

  10. Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia

    ... (OS) durations were 13.2, 19.1, and 14.9 months. Neutropenia was the most common grade 3-4 adverse event. These results ...

    Research Article last updated 05/22/2014 - 9:28am.